<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527202</url>
  </required_header>
  <id_info>
    <org_study_id>BTXneurop-1</org_study_id>
    <nct_id>NCT00527202</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Botox to Treat Neuropathic Pain</brief_title>
  <official_title>Randomized Placebo-controlled Study of the Efficacy of Botulinum Toxin Type A (Botox) in Spontaneous Pain and Allodynia Related to Traumatic Nerve Injury or Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ambroise Paré Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Ambroise Paré Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives : to investigate the analgesic effects and safety of intradermal botulinum toxin A&#xD;
      injection in the treatment of focal painful neuropathies (eg, postherpetic neuralgia, nerve&#xD;
      trauma)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be randomized, performed in parallel group and double blind versus saline and&#xD;
      will include 30 patients. Botulinum toxin injection will be injected intradermally in the&#xD;
      painful area (one single injection) following a method adapted from that used in&#xD;
      hyperhidrosis. The patients will be followed for 6 months after the injection. Primary&#xD;
      outcome will be self-reported pain from the patients diaries. Secondary outcomes will be&#xD;
      neuropathic symptoms, quality of life, allodynia to brush and pressure, detection and pain&#xD;
      thresholds, proportion of responders, pain relief and clinical global impression. Clinical&#xD;
      assessment will take place before injection then at 1 month, 3 months and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported pain (numerical scales) on patients diaries</measure>
    <time_frame>prospective</time_frame>
    <description>pain intensity on numerical rating scales</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean pain (VAS) at each visit Quality of life Proportion of responders % pain relief Clinical global impression Assessment of blindedness</measure>
    <time_frame>prospective</time_frame>
    <description>VAS for pain intensity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <condition>Nerve Trauma</condition>
  <arm_group>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment arm using botulinum toxin A max 200 U injected into the painful area using SC injections 2 cm apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline injection with the same dosages injected using the same procedure as botulinum toxin A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin A</intervention_name>
    <description>Botulinum toxin A versus saline in parallel groups</description>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>saline (placebo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  daily pain for at least 6 months of at least moderate intensity clearly attributed to&#xD;
             the nerve lesion&#xD;
&#xD;
          -  limited area of pain&#xD;
&#xD;
          -  mechanical allodynia in the painful area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication to BTXA formulation&#xD;
&#xD;
          -  coagulation disorders&#xD;
&#xD;
          -  another painful condition&#xD;
&#xD;
          -  current major depression&#xD;
&#xD;
          -  history of drug or alcohol abuse&#xD;
&#xD;
          -  compensation claim or litigation&#xD;
&#xD;
          -  facial neuropathic pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BOUHASSIRA, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM U 792</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danièle RANOUX, MD</last_name>
    <role>Study Chair</role>
    <affiliation>hôpital de Limoges (FRANCE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré, AP-HP</name>
      <address>
        <city>Boulogne-billancourt</city>
        <zip>92100f</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Ambroise Paré Paris</investigator_affiliation>
    <investigator_full_name>Nadine ATTAL</investigator_full_name>
    <investigator_title>MD PhD coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

